Studies have shown that KRAS mutations are associated with a higher tumor mutational burden (TMB), upregulated PD‐L1 expression, and increased proportion of CD8+ tumor‐infiltrating lymphocytes (TILs), which could reflect an improved response to ICIs.31, 32. This evidence concerns the gene KRAS and neoplasm.